Cyclodepsipeptides from marine sponges: Natural agents for drug research

Marine Drugs

Volumn 8, Issue 3, 2010, Pages 810-834

  Andavan, Gowri Shankar Bagavananthem ^a   Lemmens Gruber, Rosa ^a  

^a UNIVERSITY OF VIENNA   (Austria)

Author keywords

Actin polymerisation; Cyclodepsipeptides; HIV entry inhibitors; Jasplakinolide; Papuamides

Indexed keywords

ARENASTATIN A; CALLIPELTIN A; CELEBESIDE DERIVATIVE; CYCLODEPSIPEPTIDE; DOXORUBICIN; GEODIAMOLIDE A; GEODIAMOLIDE B; GEODIAMOLIDE DERIVATIVE; GEODIAMOLIDE H; GEODIAMOLIDE I; HOMOPHYMINE A; HOMOPHYMINE DERIVATIVE; JASPAMIDE; MICROSPINOSAMIDE; MIRABAMIDE A; MIRABAMIDE B; MIRABAMIDE C; MIRABAMIDE D; MIRABAMIDE DERIVATIVE; NEAMPHAMIDE A; PAPUAMIDE A; PAPUAMIDE DERIVATIVE; SPONGIDEPSIN; THEOPAPUAMIDE B; THEOPAPUAMIDE DERIVATIVE; UNCLASSIFIED DRUG; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTINEOPLASTIC AGENT; BIOLOGICAL PRODUCT; DEPSIPEPTIDE;

ACTIN FILAMENT; ACTIN POLYMERIZATION; AMINO TERMINAL SEQUENCE; ANTINEOPLASTIC ACTIVITY; ANTIVIRAL ACTIVITY; APOPTOSIS; CANCER CELL CULTURE; CELL PROTECTION; CHLORIDE TRANSPORT; DRUG CYTOTOXICITY; DRUG ISOLATION; DRUG RESEARCH; DRUG STRUCTURE; DRUG TARGETING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; IN VITRO STUDY; MOLECULAR MODEL; NONHUMAN; POLYPLOIDY; REVIEW; SARCOMA; SIGNAL TRANSDUCTION; SODIUM CALCIUM EXCHANGE; SPONGE (PORIFERA); STRUCTURE ACTIVITY RELATION; VIRUS CELL INTERACTION; VIRUS INHIBITION; ANIMAL; CELL PROLIFERATION; CHEMISTRY; DRUG DEVELOPMENT; DRUG EFFECTS; HUMAN IMMUNODEFICIENCY VIRUS; MARINE BIOLOGY; PHYSIOLOGY;

HUMAN IMMUNODEFICIENCY VIRUS 1;

ANIMALS; ANTI-HIV AGENTS; ANTINEOPLASTIC AGENTS; BIOLOGICAL PRODUCTS; CELL PROLIFERATION; DEPSIPEPTIDES; DRUG DISCOVERY; HIV; MARINE BIOLOGY; PORIFERA;

EID: 77952513547     PISSN: None     EISSN: 16603397     Source Type: Journal    
DOI: 10.3390/md8030810     Document Type: Review

References (110)

1. Jimeno, J.M. A clinical armamentarium of marine-derived anti-cancer compounds. Anticancer Drugs 2002, 13 (Suppl.1), S15-S19.
2. Vera, M.D.; Joullié, M.M. Natural products as probes of cell biology. Med. Res. Rev. 2002, 22 (2), 102-145.
3. Davies, J.S. The cyclization of peptides and depsipeptides. J. Pept. Sci. 2003, 9 (8), 471-501.
4. Sarabia, F.; Chammaa, S.; Ruiz, A.S.; Ortiz, L.M.; Herrera, F.J. Chemistry and biology of cyclic depsipeptides of medicinal and biological interest. Curr. Med. Chem. 2004, 11 (10), 1309-1332.
5. Hamada, Y.; Shioiri, T. Recent progress of the synthetic studies of biologically active marine cyclic peptides and depsipeptides. Chem. Rev. 2005, 105 (12), 4441-4482.
6. Sladic, D.; Gasic, M.J. Reactivity and biological activity of the marine sesquiterpene hydroquinone avarol and related compounds from sponges of the order Dictyoceratida. Molecules 2006, 11 (1), 1-33.
7. Gupta, L.; Talwar, A.; Chauhan, P.M. Bis and tris indole alkaloids from marine organisms, new leads for drug discovery. Curr. Med. Chem. 2007, 14 (16), 1789-1803.
8. Liu, Y., Wang, L.; Jung, J.H.; Zhang, S. Sesterterpenoids. Nat. Prod. Rep. 2007, 24 (6), 1401-1429.
9. Fotie, J.; Morgan, R.E. Depsipeptides from microorganisms: a new class of antimalarials. Mini Rev. Med. Chem. 2008, 8 (11), 1088-1094.
10. Araki, M.; Miyake, S.; Yamamura, T. Synthetic glycolipid ligands for human iNKT cells as potential therapeutic agents for immunotherapy. Curr. Med. Chem. 2008, 15 (23), 2337-2345.
11. Godo, M.; Sessler, T.; Hamar, P. Role of invariant natural killer T (iNKT) cells in systemic lupus erythematosus. Curr. Med. Chem. 2008, 15 (18), 1778-1787.
12. Skropeta, D. Deep-sea natural products. Nat. Prod. Rep. 2008, 25 (6), 1131-1166.
13. Taylor, R.E. Tedanolide and the evolution of polyketide inhibitors of eukaryotic protein synthesis. Nat. Prod. Rep. 2008, 25 (5), 854-861.
14. Blunt, J.W.; Copp, B.R.; Hu, W.P.; Munro, M.H.G.; Northcote, P.T.; Prinsep, M.R. Marine natural products. Nat. Prod. Rep. 2008, 25 (1), 35-94.
15. Provencio, M.; Sánchez, A.; Gasent, J.; Gómez, P.; Rosell, R. Cancer treatments: Can we find treasures at the bottom of the sea? Clin. Lung Cancer 2009, 10 (4), 295-300.
16. Barnathan, G. Non-methylene-interrupted fatty acids from marine invertebrates: Occurrence, characterization and biological properties. Biochimie 2009, 91 (6), 671-678.
17. Fusetani, N.; Kem, W. Marine toxins: an overview. Prog. Mol. Subcell. Biol. 2009, 46, 1-44.
18. Gademann, K.; Kobylinska, J. Antimalarial natural products of marine and freshwater origin. Chem. Rec. 2009, 9 (3), 187-198.
19. Laport, M.S.; Santos, O.C.; Muricy, G. Marine sponges: potential sources of new antimicrobial drugs. Curr. Pharm. Biotechnol. 2009, 10 (1), 86-105.
20. Paterson, I.; Dalby, S.M. Synthesis and stereochemical determination of the spirastrellolides. Nat. Prod. Rep. 2009, 26 (7), 865-873.
21. Wu, L.; Gabriel, C.L.; Parekh, V.V.; Van Kaer, L. Invariant natural killer T cells: innate-like T cells with potent immunomodulatory activities. Tissue Antigens 2009, 73 (6), 535-545.
22. Muñoz-Alonso, M.J.; González-Santiago, L.; Martínez, T.; Losada, A.; Galmarini, C.M.; Muñoz, A. The mechanism of action of plitidepsin. Curr. Opin. Investig. Drugs 2009, 10 (6), 536-542.
23. Andjelic, C.D.; Planelles, V.; Barrows, L.R. Characterizing the anti-HIV activity of papuamide A. Mar. Drugs 2008, 6 (4), 528-549.
24. Plaza, A.; Gustchina, E.; Baker, H.L.; Kelly, M.; Bewley, C.A. Mirabamides A-D, depsipeptides from the sponge Siliquariaspongia mirabilis that inhibit HIV-1 fusion. J. Nat. Prod. 2007, 70 (11), 1753-1760.
25. Tan, J.J.; Cong, X.J.; Hu, L.M.; Wang, C.X.; Jia, L.; Liang, X.J. Therapeutic strategies underpinning the development of novel techniques for the treatment of HIV infection. Drug Discov. Today 2010, 15, 186-197.
26. Hamann, M.T.; Otto, C.S.; Scheuer, P.J.; Dunbar, D.C. Kahalalides: Bioactive peptides from a marine mollusk Elysia rufescens and its algal diet bryopsis sp. J. Org. Chem. 1996, 61, 6594-6600.
27. Rademaker-Lakhai, J.M.; Horenblas, S.; Meinhardt, W.; Stokvis, E.; de Reijke, T.M.; Jimeno, J.M.; Lopez-Lazaro, L.; Lopez Martin, J.A.; Beijnen, J.H.; Schellens, J.H. Phase I clinical and pharmacokinetic study of kahalalide F in patients with advanced androgen refractory prostate cancer. Clin. Cancer Res. 2005, 11, 1854-1862.
28. Pardo, B.; Paz-Ares, L.; Tabernero, J.; Ciruelos, E.; Garcia, M.; Salazar, R.; López, A.; Blanco, M.; Jimeno, J.; Izquierdo, M.A.; Triqo, J.M. Phase I clinical and pharmacokinetic study of kahalalide F administered weekly as a 1-hour infusion to patients with advanced solid tumors. Clin. Cancer Res. 2008, 14, 1116-1123.
29. Martin-Algara, S.; Espinosa, E.; Rubió, J.; López, J.J.; Manzano, J.L.; Plazaola, A.; Tanovic, A.; Paz-Ares, L. Phase II study of weekly kahalalide F in patients with advanced malignant melanoma. Eur. J. Cancer 2009, 45 (5), 732-735.
30. Faivre, S.; Chièze, S.; Delbaldo C.; Ady-vago, N.; Guzman, C.; Lopez-Lazaro, L.; Lozahic, S.; Jimeno, J.; Pico, F.; Armand, J.P.; Lopez Martin, J.A.; Raymond, E. Phase I and Pharmacokinetic Study of Aplindine, a New Marine Cyclodepsipeptide in Patients With Advanced Malignancies. J. Clin. Oncol. 2005, 23, 7871-7880.
31. Maroun, J.A.; Belanger, K.; Seymour, L.; Matthews, S.; Roach, J.; Dionne, J.; Soulieres, D.; Stewart, D.; Goel, R.; Charpentier, D.; Goss, G.; Tomiak, E.; Yau, J.; Jimeno, J.; Chiritescu, G. Phase I study of Aplidine in a dailyx5 one-hour infusion every 3 weeks in patients with solid tumors refractory to standard therapy. A National Cancer Institute of Canada Clinical Trials Group study, NCIC CTG IND 115. Ann. Oncol. 2006, 17, 1371-1378.
32. Mitsiades, C.S.; Ocio, E.M.; Pandiella, A.; Maiso, P.; Gajate, C.; Garayoa, M.; Vilanova, D.; Montero, J.C.; Mitsiades, N.; McMullan, C.J.; Munshi, N.C.; Hideshima, T.; Chauhan, D.; Aviles, P.; Otero, G.; Faircloth, G.; Mateos, M.V.; Richardson, P.G.; Mollinedo, F.; San-Miguel, J.F.; Anderson, K.C. Aplidin, a marine organism-derived compound with potent antimyeloma activity in vitro and in vivo. Cancer Res. 2008, 68 (13), 5216-5225.
33. Peschel, C.; Hartmann, J.T.; Schmittel, A.; Bokemeyer, C.; Schneller, F.; Keilholz, U.; Buchheidt, D.; Millan, S.; Izquierdo, M.A.; Hofheinz, R.D. Phase II study of plitidepsin in pretreated patients with locally advanced or metastatic non-small cell lung cancer. Lung Cancer 2008, 60, 374-380.
34. Izqierdo, M.A.; Bowman, A.; García, M.; Jodrell, D.; Martinez, M.; Pardo, B.; Gómez, J.; López-Martin, J.A.; Jimeno, J.; Germá, J.R.; Smyth, J.F. Phase I clinical and pharmacokinetic study of plitidepsin as a 1-hour weekly intravenous infusion in patients with advanced solid tumors. Clin. Cancer Res. 2008, 14, 3105-3112.
35. Nalda-Molina, R.; Valenzuela, B.; Ramon-Lopez, A.; Miguel-Lillo, B.; Soro-Matos, A.; Perez-Ruixo, J.J. Population pharmacokinetics meta-analysis of plitidepsin (Aplidin®) in cancer subjects. Cancer Chemother. Pharmacol. 2009, 64 (1), 97-108.
36. Morton, C.L.; Houghton, P.J.; Gorlick, R.; Kolb, E.A.; Lock, R.; Carol, H.; Keir, S.T.; Reynolds C.P.; Kang, M.H.; Maris, J.M.; Billups, C.; Smith, M.A. Initial testing of aplidin by the pediatric pre-clinical testing program. Pediatr. Blood Cancer 2009, 53 (3), 509-512.
37. Dumez, H.; Gallardo, E.; Culine, S.; Galceran, J.C.; Schöffski, P.; Droz, J.P.; Extremera, S.; Szyldergemajn, S.; Fléchon, A. Phase II study of biweekly plitidepsin as second-line therapy for advanced or metastatic ttransitional cell carcinoma of the urothelium. Mar. Drugs 2009, 7 (3), 451-463.
38. Rockwell, S.; Liu, Y. Aplidin as a potential adjunct to radiation therapy: in vitro studies. Int. J. Radiat. Biol. 2010, 86 (1), 63-70.
39. Liang, B.; Carroll, P.J.; Joullie, M.M. Progress toward the total synthesis of callipeltin A (I): asymmetric synthesis of (3S,4R)-3,4- dimethylglutamine. Org. Lett. 2000, 2 (26), 4157-4160.
40. Thoen, J.C.; Morales-Ramos, Á.I.; Lipton, M.A. Synthesis of the unnatural amino acid AGDHE, a constituent of the cyclic ddepsipeptides callipeltins A and D. Org. Lett. 2002, 4 (25), 4455-4458.
41. Turk, J.A.; Visbal, G.S.; Lipton, M.A. Asymmetric synthesis of four diastereomers of 3-hydroxy-2,4,6-trimethylheptanoic acid: proof of configurational assignment. J. Org. Chem. 2003, 68 (20), 7841-7844.
42. Okamoto, N.; Hara, O.; Makino, K.; Hamada, Y. Diastereoselective synthesis of all stereoisomers of beta-methoxytyrosine, a component of papuamides. J. Org. Chem. 2002, 67 (26), 9210-9215.
43. Hansen, D.B.; Wan, X.; Carroll, P.J.; Joullié, M.M. Stereoselective synthesis of four stereoisomers of beta-methoxytyrosine, a component of callipeltin A. J. Org. Chem. 2005, 70 (8), 3120-3126.
44. Oku, N.; Gustafson, K.R.; Cartner, L.K.; Wilson, J.A.; Shigematsu, N.; Hess, S.; Pannell, L.K.; Boyd, M.R.; McMahon, J.B. Neamphamide A, a new HIV-inhibitory depsipeptide from the Papua New Guinea marine sponge Neamphius huxleyi. J. Nat. Prod. 2004, 67 (8), 1407-1411.
45. Zampella, A.; D'Orsi, R.; Sepe, V.; Casapullo, A.; Monti, M.C.; D'Auria, M.V. Concise synthesis of all stereoisomers of beta-methoxytyrosine and determination of the absolute configuration of the residue in callipeltin A. Org. Lett. 2005, 7 (16), 3585-3588.
46. Calimsiz, S.; Morales Ramos, A.I.; Lipton, M.A. Solid-phase synthesis and configurational reassigment of callipeltin E. Implications for the structures of callipeltins A and B. J. Org. Chem. 2006, 71 (17), 6351-6356.
47. Krishnamoorthy, R.; Vasquez-Serrano, L.D.; Turk, J.A.; Kowalski, J.A.; Benson, A.G.; Breaux, N.T.; Lipton, M.A. Solid-phase total synthesis and structure proof of callipeltin B. J. Am. Chem. Soc. 2006, 128 (48), 15392-15393.
48. Xie, W.; Ding, D.; Zi, W.; Li, G.; Ma, D. Total synthesis and structure assignment of papuamide B, a potent marine cyclodepsipeptide with anti-HIV properties. Angew. Chem. Int. Ed. Engl. 2008, 47 (15), 2844-2848.
49. Zampella, A.; D'Auria, V.; Gomez Paloma, L.; Casapullo, A.; Minale, L.; Debitus, C.; Henin, Y. Callipeltin A, an anti-HIV cyclic depsipeptide from the new Caledonian Listhistida sponge Calipellta sp. J. Am. Chem. Soc. 1996, 118, 6202-6209.
50. Plaza, A.; Bifulco, G.; Keffer, J.L.; Lloyd, J.R.; Baker, H.L.; Bewley, C.A. Celebesides A-C and theopapuamides B-D, depsipeptides from an Indonesian sponge that inhibit HIV-1 entry. J. Org. Chem. 2009, 74 (2), 504-512.
51. Zampella, A.; Sepe, V.; Luciano, P.; Bellotta, F.; Monti, M.C.; D'Auria, M.V.; Jepsen, T.; Petek, S.; Adeline, M.T.; Laprévôte, O.; Aubertin, A.M.; Debitus, C.; Poupat, C.; Ahond, A. Homophymine A, an anti-HIV cyclodepsipeptide from the sponge Homophymia sp. J. Org. Chem. 2008, 73 (14), 5319-5327.
52. Rashid, M.A.; Gustafson, K.R.; Cartner, L.K.; Shigematsu, N.; Pannell, L.K.; Boyd, M.R. Microspinosamide, a new HIV-inhibitory cyclic depsipeptide from the marine sponge Sidonops microspinosa. J. Nat. Prod. 2001, 64 (1), 117-121.
53. Ford P.W.; Gustafson, K.R.; McKee, T.C.; Shigematsu, N.; Maurizi, L.K.; Pannell, L.K.; Williams, D.E.; Dilip de Silva, E.; Lassota, P.; Allen, T.M.; Van Soest, R.; Andersen, R.J.; Boyd, M.R. Papuamides A-D, HIV inhibitory and cytotoxic depsipeptides from the sponges Theonella mirabilis and Theonella swinhoei collected in Papua New Guinea. J. Am. Chem. Soc. 1999, 121, 5899-5909.
54. Oku, N.; Krishnamoorthy, R.; Benson, A.G.; Ferguson, R.L.; Lipton, M.A.; Phillips, L.R.; Gustafson, K.R.; McMahon, J.B. Complete stereochemistry of neamphamide A and absolute configuration of the beta-methoxytyrosine residue in papuamide B. J. Org. Chem. 2005, 70 (17), 6842-6847.
55. Ratnayake, A.S.; Bugni, T.S.; Feng, X.; Harper, M.K.; Skalicky, J.J.; Mohammed, K.A.; Andjelic, C.D.; Barrows, L.R.; Ireland, C.M. Theopapuamide, a cyclic depsipeptide from a Papua New Guinea lithistid sponge Theonella swinhoei. J. Nat. Prod. 2006, 69 (11), 1582-1586.
56. Dalgleish, A.G The pathogenesis of AIDS: classical and alternative views. J. R. Coll. Physicians Lond. 1992, 26 (2), 152-158.
57. McDougal, J.S.; Klatzmann, D.R.; Maddon, P.J. CD4-gp120 interactions. Curr. Opin. Immunol. 1991, 4, 552-558.
58. Rizzuto, C.D.; Wyatt, R.; Hernández-Ramos, N.; Sun, Y.; Kwong, P.D.; Hendrickson, W.A.; Sodroski, J. A conserved HIV gp120 glycoprotein structure involved in chemokine receptor binding. Science 1998, 280 (5371), 1949-1953
59. Liu, S.; Wu, S.; Jiang, S. HIV entry inhibitors targeting gp41: from polypeptides to small-molecule compounds. Curr. Pharm. Des. 2007, 13 (2), 143-162.
60. Doms, R.W.; Moore, J.P. HIV-1 membrane fusion: targets of opportunity. J. Cell. Biol. 2000, 151 (2), F9-14.
61. Chan, D.C.; Fass, D.; Berger, J.M.; Kim, P.S. Core structure of gp41 from the HIV envelope glycoprotein. Cell 1997, 89 (2), 263-273.
62. Tan, K.; Liu, J.; Wang, J.; Shen, S.; Lu, M. Atomic structure of a thermostable subdomain of HIV-1 gp41. Proc. Natl. Acad. Sci. USA 1997, 94 (23), 12303-12308.
63. Weissenhorn, W.; Dessen, A.; Harrison, S.C.; Skehel, J.J.; Wiley, D.C. Atomic structure of the ectodomain from HIV-1 gp41. Nature 1997, 387 (6631), 426-430.
64. Volpon, L.; Besson, F.; Lancelin, J.M. NMR structure of active and inactive forms of the sterol-dependent antifungal antibiotic bacillomycin L. Eur. J. Biochem. 1999, 264 (1), 200-210.
65. Campbell, S.M.; Crowe, S.M.; Mak, J. Virion-associated cholesterol is critical for the maintenance of HIV-1 structure and infectivity. AIDS 2002, 16 (17), 2253-2261.
66. Raulin, J. Human immunodeficiency virus and host cell lipids. Interesting pathways in research for a new HIV therapy. Prog. Lipid Res. 2002, 41 (1), 27-65.
67. Hayot, C.; Debeir, O.; Van Ham, P.; Van Damme, M.; Kiss, R.; Decaestecker, C. Characterization of the activities of actin-affecting drugs on tumor cell migration. Toxicol. Appl. Pharmacol. 2006, 211 (1), 30-40.
68. Terracciano, S.; Bruno, I.; D'Amico, E.; Bifulco, G.; Zampella, A.; Sepe, V.; Smith C.D.; Riccio, R. Synthetic and pharmacological studies on new simplified analogues of the potent actintargeting Jaspamide. Bioorg. Med. Chem. 2008, 16 (13), 6580-6588.
69. Tabudravu, J.N.; Morris, L.A.; Milne, B.F.; Jaspars, M. Conformational studies of free and Li+ complexed jasplakinolide, a cyclic depsipeptide from the Fijian marine sponge Jaspis splendens. Org. Biomol. Chem. 2005, 3 (5), 745-749.
70. Trevisi, L.; Bova, S.; Cargnelli, G.; Danieli-Betto, D.; Floreani, M.; Germinario, E.; D'Auria, M.V.; Luciani, S. Callipeltin A, a cyclic depsipeptide inhibitor of the cardiac sodium-calcium exchanger and positive inotropic agent. Biochem. Biophys. Res. Commun. 2000, 279 (1), 219-222.
71. Krishnamoorthy, R.; Richardson, B.L.; Lipton, M.A. Synthesis and cytotoxicity of desmethoxycallipeltin B: lack of a quinone methide for the cytotoxicity of callipeltin B. Bioorg. Med. Chem. Lett. 2007, 17 (18), 5136-5138.
72. Grassia, A.; Bruno, I.; Debitus, C.; Marzocco, S.; Pinto, A.; Gomez-Paloma, L.; Riccio, R. Spongidepsin, a new cytotoxic macrolide from Spongia sp. Tetrahedron 2001, 57, 6257-6260.
73. Ferrie, L.; Reymond, S.; Capdevielle, P.; Cossy, J. Total synthesis of (-)-spongidepsin. Org. Lett. 2006, 8 (16), 3441-3443.
74. Ghosh, A.; Xu, X. Assignment of absolute stereochemistry and total synthesis of (-)-spongidepsin. Org. Lett. 2004, 6 (12), 2055-2058.
75. Zhu, G.; Negishi, E. Fully reagent-controlled asymmetric synthesis of (-)-spongidepsin via the Zr-catalyzed asymmetric carboalumination of alkenes (ZACA reaction). Org. Lett. 2007, 9 (15), 2771-2774.
76. Zampella, A.; Sepe, V.; Bellotta, F.; Luciano, P.; D'Auria, M.V.; Cresteil, T.; Debitus, C.; Petek, S.; Poupat, C.; Ahond, A. Homophymines B-E and A1-E1, a family of bioactive cyclodepsipeptides from the sponge Homophymia sp. Org. Biomol. Chem. 2009, 7 (19), 4037-4044.
77. Stehn, J.R.; Schevzoy, G.; O'Neill, G.M.; Gunning, P.W. Specialisation of the tropomyosin composition of actin filaments provides new potential targets for chemotherapy. Curr Cancer Drug Targets 2006, 6 (3), 245-256.
78. Merajver, S.D.; Usmani, S.Z. Multifaceted role of Rho proteins in angiogenesis. J. Mammary Gland Biol. Neoplasia 2005, 10 (4), 291-1198
79. Dummler, B.; Ohshiro, K.; Kumar, R.; Field, J. Pak protein kinases and their role in cancer. Cancer Metastasis Rev. 2009, 28 (1-2), 51-63.
80. Bubb, M.R.; Senderowicz, A.M.J.; Sausville, E.A.; Duncan, K.L.K.; Korn, E.D. Jasplakinolide, a cytotoxic natural product, induces actin polymerization and competitively inhibits the binding of phalloidin to F-actin. J. Biol. Chem. 1994, 269 (21), 14869-14871.
81. Ridley, A.J. Rho-related proteins: actin cytoskeleton and cell cycle. Curr. Opin. Genet. Dev. 1995, 5(1), 24-30.
82. Fabian, I.; Shur, I.; Bleiberg, I.; Rudi, A.; Kashman, Y.; Lishner, M. Growth modulation and differentiation of acute myeloid leukemia cells by jaspamide. Exp. Hematol. 1995, 23 (7), 583-587.
83. Fabian, I.; Halperin, D.; Lefter, S.; Mittelman, L.; Altstock, R.T.; Seaon, O.; Tsarfaty, I. Alteration of actin organization by jaspamide inhibits ruffling, but not phagocytosis or oxidative burst, in HL-60 cells and human monocytes. Blood 1999, 93 (11), 3994-4005.
84. Bubb, M.R.; Spector, I.; Beyer, B.B.; Fosen, K.M. Effects of jasplakinolide on the kinetics of actin polymerization. An explanation for certain in vivo observations. J. Biol. Chem. 2000, 275 (7), 5163-5170.
85. Ou, G.S.; Chen, Z.L.; Yuan, M. Jasplakinolide reversibly disrupts actin filaments in suspension-cultured tobacco BY-2 cells. Protoplasma 2002, 219 (3-4), 168-175.
86. Tinto, W.F.; Lough, A.J.; McLean, S.; Reynolds, W.F.; Yu, M.; Chan, W.R. Geodiamolides H and I, further cyclodepsipeptides from the marine sponge Geodia sp. Tetrahedron 1998, 54 (18), 4451-4458.
87. Rangel, M.; Prado, M.; Konno, K.; Naoki, H.; Freitas, J.C.; Machado-Santelli, G.M. Cytoskeleton alterations induced by Geodia corticostylifera depsipeptides in breast cancer cells. Peptides 2006, 27 (9), 2047-2057.
88. Freitas, V.M.; Rangel, M.; Bisson, L.F.; Jaeger, R.G.; Machado-Santelli, G.M. The geodiamolide H, derived from Brazilian sponge Geodia corticostylifera, regulates actin cytoskeleton, migration and invasion of breast cancer cells cultured in three-dimensional environment. J. Cell. Physiol. 2008, 216 (3), 583-594.
89. Nakazawa, H.; Kitano, K.; Cioca, D.; Ishikawa, M.; Ueno, M.; Ishida, F.; Kiyosawa, K. Induction of polyploidization by jaspamide in HL-60 cells. Acta Haematol. 2000, 104 (2-3), 65-71.
90. Odaka, C.; Sanders, M.L.; Crews, P. Jasplakinolide induces apoptosis in various transformed cell lines by a caspase-3-like protease-dependent pathway. Clin. Diagn. Lab. Immunol. 2000, 7 (6), 947-952.
91. Cioca, D.P.; Kitano, K. Induction of apoptosis and CD10/neutral endopeptidase expression by jaspamide in HL-60 line cells. Cell. Mol. Life Sci. 2002, 59 (8), 1377-1387.
92. Kobayashi, M.; Wang, W.; Ohyabu, N.; Kurosu, M.; Kitagawa, I. Improved total synthesis and structure-activity relationship of arenastatin A, a potent cytotoxic spongean depsipeptide. Chem. Pharm. Bull. (Tokyo) 1995, 43 (9), 1598-1600.
93. Koiso, Y.; Morita, K.; Kobayashi, M.; Wang, W.; Ohyabu, N.; Iwasaki, S. Effects of arenastatin A and its synthetic analogs on microtubule assembly. Chem. Biol. Interact. 1996, 102 (3), 183-191.
94. Morita, K.; Koiso, Y.; Hashimoto, Y.; Kobayashi, M.; Wang, W.; Ohyabu, N.; Iwasaki, S. Interaction of arenastatin A with porcine brain tubulin. Biol. Pharm. Bull. 1997, 20 (2), 171-174.
95. Kotoku, N.; Kato, T.; Narumi, F.; Ohtani, E.; Kamada, S.; Aoki, S.; Okada, N.; Nakagawa, S.; Kobayashi, M. Synthesis of 15,20-triamide analogue with polar substituent on the phenyl ring of arenastatin A, an extremely potent cytotoxic spongean depsipeptide. Bioorg. Med. Chem. 2006, 14 (22), 7446-7457.
96. Rao, J.Y.; Jin, Y.S.; Zheng, Q.L.; Cheng, J.; Tai, J.; Hemstreet III, G.P. Alterations of the actin polymerization status as an apoptotic morphological effector in HL-60 cells. J. Cell. Biochem. 1999, 75 (4), 686-697.
97. Marimganti, S.; Yasmeen, S.; Fischer, D.; Maier, M. Synthesis of jasplakinolide analogues containing a novel omega-amino acid. Chemistry 2005, 11 (22), 6687-6700.
98. Hu, T.S.; Tannert, R.; Arndt, H.D.; Waldmann, H. Solid-phase based synthesis of jasplakinolide analogs by intramolecular azide-alkyne cycloadditions. Chem. Commun. (Camb) 2007, 3942-3944.
99. Terracciano, S.; Bruno, I.; Bifulco, G.; Avallone, E.; Smith, C.D.; Gomez-Paloma, L.; Riccio, R. Synthesis, solution structure, and bioactivity of six new simplified analogues of the natural cyclodepsipeptide jaspamide. Bioorg. Med. Chem. 2005, 13 (17), 5225-5239.
100. Eggen, M.; Mossman, C.J.; Buck, S.B.; Nair, S.K.; Bhat, L.; Ali, S.M.; reiff, E.A.; Boge, T.C.; Georg, G.I. Total synthesis of cryptophycin-24 (Arenastatin A) amenable to structural modifications in the C16 side chain. J. Org. Chem. 2000, 65 (23), 7792-7799.
101. Murakami, N.; Wang, W.; Tamura, S.; Kobayashi, M. Synthesis and biological property of carba and 20-deoxo analogues of arenastatin A. Bioorg. Med. Chem. Lett. 2000, 10 (16), 1823-1826.
102. Murakami, N.; Tamura, S.; Koyama, K.; Sugimoto, M.; Maekawa, R.; Kobayashi, M. New analogue of arenastatin A, a potent cytotoxic spongean depsipeptide, with anti-tumor activity. Bioorg. Med. Chem. Lett. 2004, 14 (10), 2597-2601.
103. Shaw, M.K.; Tilney, L.G. Induction of an acrosomal process in Toxoplasma gondii: visualization of actin filaments in a protozoan parasite. Proc. Natl. Acad. Sci. USA 1999, 96 (16), 9095-19009
104. Terada, Y.; Simerly, C.; Schatten, G. Microfilament stabilization by jasplakinolide arrests oocyte maturation, cortical granule exocytosis, sperm incorporation cone resorption, and cell-cycle progression, but not DNA replication, during fertilization in mice. Mol. Reprod. Dev. 2000, 56 (1), 89-98.
105. Di Campli, A.; Valderrama, F.; Babià, T.; De Matteis, M.A.; Liuni, A.; Egea, G. Morphological changes in the Golgi complex correlate with actin cytoskeleton rearrangements. Cell. Motil. Cytoskeleton 1999, 43 (4), 334-348.
106. Cramer, L.P. Role of actin-filament disassembly in lamellipodium protrusion in motile cells revealed using the drug jasplakinolide. Curr. Biol. 1999, 9 (19), 1095-1105.
107. Posey, S.C.; Bierer, B.E. Actin stabilization by jasplakinolide enhances apoptosis induced by cytokine deprivation. J. Biol. Chem. 1999, 274 (7), 4259-4265.
108. Holzinger, A.; Meindl, U. Jasplakinolide, a novel actin targeting peptide, inhibits cell growth and induces actin filament polymerization in the green alga Micrasterias. Cell. Motil. Cytoskeleton 1997, 38 (4), 365-372.
109. Trevisi, L.; Cargnelli, G.; Ceolotto, G.; Papparella, I.; Semplicini, A.; Zampella, A.; D'Auria, M.V.; Luciani, S. Callipeltin A: sodium ionophore effect and tension development in vascular smooth muscle. Biochem. Pharmacol. 2004, 68 (7), 1331-1338.
110. Matthews, J.B.; Smith, J.A.; Hrnjez, B.J. Effects of F-actin stabilization or disassembly on epithelial Cl- secretion and Na-K-2Cl cotransport. Am. J. Physiol. 1997, 272, C254-C262.